New Study: CRP Reveals Stroke Recurrence Risk That Cholesterol Tests Miss

When a person has a stroke, the standard prevention strategy afterward focuses heavily on controlling cholesterol, blood pressure, and antiplatelet therapy. These measures are well-founded and save lives. But a growing body of research, including a new study just published this month in one of cardiology's highest-impact journals, is making clear that a significant proportion of stroke survivors remain at elevated risk even after their lipid numbers reach guideline targets. The reason, the evidence suggests, is inflammation. And the best widely available blood marker for tracking that inflammation is C-reactive protein.

Understanding what the new research found, what it means, and why inflammation persists as a distinct risk driver from cholesterol is worth examining carefully, because the practical implications reach well beyond stroke survivors to anyone monitoring their cardiovascular and general wellness.

What the New JAHA Study Found

The study, published September 9, 2026 in the Journal of the American Heart Association, followed 942 patients hospitalized with ischemic stroke and tracked major adverse cardiovascular events over one year. Researchers at Tokyo Women's Medical University divided patients based on whether they had intracranial atherosclerotic stenosis (ICAS), a narrowing or partial blockage of the arteries supplying blood directly to the brain. Of the 942 patients (mean age 71.2 years), 262 (27.8%) had this arterial narrowing, which is a particularly high-risk condition known for a substantially elevated rate of recurrent stroke compared with other stroke subtypes.

In the subgroup with intracranial atherosclerotic stenosis, elevated hsCRP above the median threshold of 2.0 mg/L was associated with dramatically worse outcomes. Patients with high hsCRP had a 28.5% rate of major adverse cardiovascular events during the year, compared with 15.9% in patients with lower CRP levels. That difference persisted after the researchers adjusted for age, sex, diabetes, hypertension, LDL cholesterol, antiplatelet treatment, and other standard confounders. In those fully adjusted models, hsCRP at or above 2.0 mg/L was independently associated with a hazard ratio of 2.01, meaning roughly double the cardiovascular event risk, with a 95% confidence interval of 1.12 to 3.59.

A separate analysis derived an optimal CRP cutoff using receiver operating characteristic methods, and the result was 2.9 mg/L, which was associated with an even sharper hazard ratio of 2.86. The researchers also tested interleukin-6 (IL-6), a pro-inflammatory cytokine often measured alongside CRP, and found that after full adjustment IL-6 lost its independent significance while hsCRP retained it. That divergence matters: it suggests that in this population, CRP is capturing inflammatory signal that goes beyond what IL-6 alone reflects, and that CRP is the more robust standalone predictor of the two.

Crucially, both biomarkers remained predictive of cardiovascular events in the subgroup of patients who had achieved LDL cholesterol below 100 mg/dL, a level considered well-controlled by most clinical guidelines. This finding directly addresses the clinical question of whether inflammation measurement adds anything in patients who are already treating their cholesterol. For stroke survivors with intracranial atherosclerotic disease, the answer appears to be: yes, it adds a great deal. The study concludes that "baseline hsCRP may improve risk stratification in ICAS-related stroke by identifying residual inflammatory risk beyond conventional risk factors." (Hoshino et al., JAHA, 2026)

What Is Intracranial Atherosclerotic Stenosis and Why Does It Matter

Intracranial atherosclerotic stenosis is one of the most common causes of ischemic stroke globally, and it carries the highest rate of stroke recurrence among all identifiable stroke subtypes. It occurs when atherosclerotic plaque narrows the lumen of the major arteries running inside the skull. The middle cerebral artery, the basilar artery, and the internal carotid artery above the skull base are common sites. Narrowing of 50% or more is the conventional threshold used in clinical practice and in research, and beyond that level the risk of a second event within months to years is substantially elevated.

Inflammation is not incidental to this process; it is central to it. Atherosclerosis develops through a sequence in which lipid accumulation in the arterial wall triggers an immune response, macrophages infiltrate the plaque, and chronic inflammatory signaling maintains a state that destabilizes the plaque over time. CRP is not merely a signal that inflammation is happening somewhere; it is also thought by some researchers to participate actively in the progression of atherosclerosis through interactions with complement, Fc-gamma receptors, and LDL particles. This means that in a condition defined by arterial inflammation, a blood CRP measurement is capturing something mechanistically relevant to the disease process itself, not just a downstream consequence.

The population studied by the JAHA team, older adults who had already experienced at least one ischemic stroke and who carried intracranial arterial disease, represents a group where inflammation may be especially persistent. The atherosclerotic burden is established, the prior stroke itself triggered an acute inflammatory response, and the ongoing smoldering inflammation that characterizes chronic atherosclerosis is unlikely to resolve on its own. In this context, the elevation in CRP reflects not transient illness but the background state of a disease process that is actively ongoing.

The Residual Risk Problem in Cardiovascular Medicine

The concept of residual cardiovascular risk has become one of the central challenges in cardiology over the past two decades. Clinical trials of statins and other LDL-lowering treatments have consistently shown meaningful reductions in heart attack and stroke, yet even in the best-treated patient populations, a substantial fraction of events continue to occur. Researchers have spent years trying to characterize what drives this residual risk. Two broad categories have emerged: residual lipid risk, captured by markers like triglyceride-rich remnant lipoproteins and Lp(a), and residual inflammatory risk, captured most practically by hsCRP.

A converging body of evidence now suggests that these two pathways are at least partially independent of each other, meaning that addressing one does not fully address the other. A study published in June 2026 in JACC Advances enrolled 3,008 patients from the China Antihypertensive Trial in Acute Ischemic Stroke and examined outcomes over 24 months based on patients' remnant cholesterol levels and their hsCRP levels separately and in combination (Chen et al., JACC Advances, 2026). Compared with patients who had neither elevated remnant cholesterol nor elevated inflammation, patients who had both elevated remnant cholesterol and hsCRP at or above 2.0 mg/L faced a hazard ratio of 2.33 for all-cause mortality and a hazard ratio of 2.28 for stroke-specific mortality. Perhaps most meaningful for everyday function, the same combined elevation was associated with nearly double the odds of an unfavorable functional outcome at two years (odds ratio 1.91). The researchers found that adding the two markers together substantially improved risk discrimination beyond traditional risk factors alone.

What this pattern reveals is that inflammation and lipid risk are additive levers, not interchangeable ones. A person can normalize their cholesterol profile while still carrying persistent systemic inflammation, and that inflammation continues to predict harm. Conversely, a person can have normal CRP yet still carry elevated remnant lipoproteins. The implication for monitoring is that measuring one without the other leaves meaningful risk invisible.

Why Inflammation Persists Even With Cholesterol Controlled

One of the more counterintuitive aspects of cardiovascular inflammation is that it can persist at low, chronic levels for years without causing obvious symptoms, and it does not automatically resolve when cholesterol is lowered. The chronic inflammatory state that underlies atherosclerosis is driven by multiple overlapping pathways, including immune cell activation inside plaque, adipose tissue signaling in individuals carrying excess visceral fat, gut microbiome perturbations, sleep disruption, and ongoing oxidative stress. Statins have well-documented mild anti-inflammatory effects in addition to their lipid-lowering ones, and part of their cardiovascular benefit is believed to come from CRP reduction. But the degree to which any given individual's CRP falls with statin therapy varies considerably, and statins do not eliminate inflammatory risk in all patients.

A study published in the journal Age and Ageing in October 2025 examined 2,333 patients aged 75 and older with established atherosclerotic cardiovascular disease and measured both hsCRP and lipoprotein(a), two markers often discussed as separate drivers of residual risk (Bian et al., Age and Ageing, 2025). Over a median follow-up of three years, hsCRP was significantly associated with major adverse cardiovascular events (adjusted hazard ratio 1.41 for hsCRP at or above 2 mg/L, P = 0.004), while Lp(a) was not independently significant. Among patients in the highest quartile of CRP, the hazard ratio reached 1.70 compared with those in the lowest quartile. The finding that inflammation outperformed a lipid-based risk marker in this population underscores that for many high-risk individuals already on treatment, inflammatory status may be the more actionable variable.

The 2025 UK Biobank analysis of over 32,000 patients with atrial fibrillation adds further weight to this picture. Researchers followed those patients for a median of 13.3 years and documented nearly 7,000 incident heart failure cases. Patients in the highest quartile of hs-CRP had a 61% higher risk of developing heart failure compared with those in the lowest quartile, with a hazard ratio of 1.61. Even a simpler clinical cutpoint of hs-CRP at or above 2 mg/dL was associated with a 39% higher heart failure risk after full adjustment for comorbidities (Li et al., Heart Rhythm, 2025). This study used a different cardiovascular outcome and a different underlying condition from the new JAHA study, but it points toward the same conclusion: CRP reflects a layer of cardiovascular risk that persists independently of the conventional variables usually managed in clinical practice.

What CRP Levels Are Clinically Meaningful

For cardiovascular risk assessment, the relevant CRP test is high-sensitivity CRP, which can detect concentrations in the low-milligrams-per-liter range where population studies show meaningful risk differentiation. Standard CRP assays used for acute illness detection work at much higher concentrations and are not designed for this purpose. The conventional classification used in cardiovascular research places hsCRP below 1 mg/L in a lower-risk category, 1 to 3 mg/L in an intermediate category, and above 3 mg/L in the higher-risk range. The 2.0 mg/L cutoff used in the JAHA study falls within the intermediate zone and is consistent with other published literature on where clinically meaningful risk separation occurs.

It is worth noting that the same CRP cutpoints show up across populations and conditions in the literature. In the UK Biobank atrial fibrillation study, 2 mg/dL was used as the clinical threshold. In the JACC Advances stroke cohort, 2.0 mg/L was the separation point. In the residual risk analysis in older adults with ASCVD, 2 mg/L divided the groups. This convergence is not a coincidence; it reflects a threshold effect that has emerged consistently from large-scale observational data, and it is the same range that several clinical practice guidelines reference when discussing when CRP adds to risk stratification decisions.

For context, a CRP level is influenced by many factors beyond cardiovascular risk. Any active infection, injury, inflammatory condition, or recent surgery will elevate CRP acutely. For a measurement to reflect background cardiovascular inflammatory risk rather than a transient response to illness, it should be taken when the person is in a stable, healthy state. Standard guidance suggests that a CRP above 10 mg/L should prompt investigation for an acute cause before interpreting the result as reflecting chronic cardiovascular risk. Persistent elevation in the 1 to 10 mg/L range in the absence of acute illness is the zone where cardiovascular relevance is most clearly established.

What This Means for Individual Wellness Monitoring

For most healthy individuals, the research on residual inflammatory risk offers a practical message rather than a cause for alarm. Most people who have not had a stroke or cardiovascular event and who are not managing cardiovascular disease do not face the level of residual risk studied in these papers. The populations in these studies had established disease, prior strokes, and significant arterial disease. But the underlying principle extends broadly: cholesterol is one window into cardiovascular wellness and inflammation is a different, partly independent window, and looking through only one of them leaves some risk invisible.

The lifestyle levers that reduce inflammation are largely the same ones that reduce cardiovascular risk through multiple other pathways. Regular moderate-intensity physical activity, a diet centered on whole foods with limited ultra-processed components, sufficient sleep, not smoking, and managing excess visceral fat all contribute to lower CRP alongside their other benefits. For someone who wants to know whether these lifestyle choices are moving the needle, a CRP measurement provides feedback that lipid testing alone does not.

CRP tracking is a general wellness tool, not a diagnostic test, and a single measurement tells you less than a trend over time. Because CRP fluctuates with minor day-to-day changes in health status, a single number needs to be interpreted with that variability in mind. Anyone who finds persistently elevated CRP on repeated testing should discuss the finding with a healthcare provider, as it may warrant investigation and is one data point among many that a clinician would consider alongside full medical history, other labs, and imaging if relevant. In that conversation, the new research on residual inflammatory risk may be useful context for understanding why tracking this particular marker is worth taking seriously.

Sources

• Hoshino T, Mizuno T, Arai S, et al. Prognostic Value of Interleukin-6 and High-Sensitivity C-Reactive Protein in Stroke Associated With Intracranial Atherosclerotic Stenosis. Journal of the American Heart Association. 2026;15(18):e050279. pubmed.ncbi.nlm.nih.gov/42714409
• Chen Y, Zhu Y, Du M, et al. Impacts of Remnant Cholesterol and Residual Inflammation on Clinical Outcomes After Ischemic Stroke. JACC Advances. 2026;5(7):102880. pubmed.ncbi.nlm.nih.gov/42287783
• Bian X, Wang HY, Guo Y, et al. Residual atherosclerotic risk in older patients with atherosclerotic cardiovascular disease: where inflammation meets lipoprotein(a). Age and Ageing. 2025;54(11). pubmed.ncbi.nlm.nih.gov/41215573
• Li L, Su S, Wu L, et al. Inflammation and heart failure risk in atrial fibrillation: Prospective evidence from UK Biobank. Heart Rhythm. 2025;23(3):e339-e347. pubmed.ncbi.nlm.nih.gov/41241110

Frequently Asked Questions

Does CRP predict stroke recurrence risk?

Yes, according to research published in September 2026 in the Journal of the American Heart Association. The study found that elevated high-sensitivity CRP at or above 2.0 mg/L independently predicted double the risk of major adverse cardiovascular events in stroke survivors with intracranial atherosclerotic stenosis, even after adjusting for cholesterol, blood pressure, and other conventional risk factors. The association held even in patients whose LDL cholesterol was already below 100 mg/dL.

What is residual inflammatory risk?

Residual inflammatory risk refers to the elevated cardiovascular event risk that persists in some patients even after standard risk factors like LDL cholesterol and blood pressure have been well-controlled. It is captured by markers such as high-sensitivity CRP and reflects chronic low-grade inflammation in the arterial wall and surrounding tissues. Multiple large studies show that elevated CRP predicts future heart attack, stroke, and heart failure independently of cholesterol levels.

What hsCRP level is considered elevated for cardiovascular risk?

Conventional classifications used in cardiovascular research place hsCRP below 1 mg/L in a lower-risk range, 1 to 3 mg/L in an intermediate range, and above 3 mg/L in a higher-risk range. The new JAHA study found that 2.0 mg/L was a clinically meaningful threshold separating outcomes in stroke survivors, and an optimal cutoff of 2.9 mg/L predicted even higher risk. These ranges are used to assess general cardiovascular wellness and are not a substitute for a full evaluation by a healthcare provider.

Can lowering cholesterol also reduce CRP?

Statins, the most widely used cholesterol-lowering drugs, do have anti-inflammatory effects and can modestly lower hsCRP in addition to reducing LDL. However, the degree of CRP reduction varies between individuals, and statins do not eliminate inflammatory risk for all patients. Research on residual inflammatory risk shows that a meaningful proportion of well-treated cardiovascular patients still carry elevated CRP, which is why measuring it separately from cholesterol provides additional information about overall cardiovascular wellness.